FDA Approves #Incyte $INTC’s Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma https://t.co/8eHtucZxsS